WallStreetZenWallStreetZen

NASDAQ: ALPN
Alpine Immune Sciences Inc Stock

$7.95-0.03 (-0.38%)
Updated Feb 6, 2023
ALPN Price
$7.95
Fair Value Price
$10.62
Market Cap
$365.02M
52 Week Low
$4.82
52 Week High
$10.30
P/E
-4.42x
P/B
2.01x
P/S
7.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$31.82M
Earnings
-$54.07M
Gross Margin
100%
Operating Margin
-163.47%
Profit Margin
-169.9%
Debt to Equity
0.6
Operating Cash Flow
-$42M
Beta
0.31
Next Earnings
Mar 15, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ALPN Overview

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALPN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALPN ($7.95) is undervalued by 25.11% relative to our estimate of its Fair Value price of $10.62 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ALPN ($7.95) is significantly undervalued by 25.11% relative to our estimate of its Fair Value price of $10.62 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ALPN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALPN due diligence checks available for Premium users.

Be the first to know about important ALPN news, forecast changes, insider trades & much more!

ALPN News

Valuation

ALPN fair value

Fair Value of ALPN stock based on Discounted Cash Flow (DCF)
Price
$7.95
Fair Value
$10.62
Undervalued by
25.11%
ALPN ($7.95) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALPN ($7.95) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALPN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALPN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.42x
Industry
11.5x
Market
14.99x

ALPN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.01x
Industry
5.06x
ALPN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALPN's financial health

Profit margin

Revenue
$8.4M
Net Income
-$13.3M
Profit Margin
-158.6%
ALPN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALPN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$291.6M
Liabilities
$109.6M
Debt to equity
0.6
ALPN's short-term assets ($253.24M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALPN's short-term assets ($253.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALPN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ALPN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$16.3M
Investing
$25.8M
Financing
$92.8M
ALPN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALPN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ALPN$365.02M-0.38%-4.42x2.01x
MGTX$364.96M+0.49%-3.25x2.98x
ACET$367.24M-2.17%-5.99x1.16x
ALDX$362.49M+0.16%-5.58x2.23x
PMVP$368.52M-2.06%-5.08x1.41x

Alpine Immune Sciences Stock FAQ

What is Alpine Immune Sciences's quote symbol?

NASDAQ: ALPN) Alpine Immune Sciences trades on the NASDAQ under the ticker symbol ALPN. Alpine Immune Sciences stock quotes can also be displayed as NASDAQ: ALPN.

If you're new to stock investing, here's how to buy Alpine Immune Sciences stock.

What is the 52 week high and low for Alpine Immune Sciences (NASDAQ: ALPN)?

(NASDAQ: ALPN) Alpine Immune Sciences's 52-week high was $10.30, and its 52-week low was $4.82. It is currently -22.82% from its 52-week high and 64.94% from its 52-week low.

How much is Alpine Immune Sciences stock worth today?

(NASDAQ: ALPN) Alpine Immune Sciences currently has 45,914,433 outstanding shares. With Alpine Immune Sciences stock trading at $7.95 per share, the total value of Alpine Immune Sciences stock (market capitalization) is $365.02M.

Alpine Immune Sciences stock was originally listed at a price of $59.68 in Jun 17, 2015. If you had invested in Alpine Immune Sciences stock at $59.68, your return over the last 7 years would have been -86.68%, for an annualized return of -25.02% (not including any dividends or dividend reinvestments).

How much is Alpine Immune Sciences's stock price per share?

(NASDAQ: ALPN) Alpine Immune Sciences stock price per share is $7.95 today (as of Feb 6, 2023).

What is Alpine Immune Sciences's Market Cap?

(NASDAQ: ALPN) Alpine Immune Sciences's market cap is $365.02M, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Alpine Immune Sciences's market cap is calculated by multiplying ALPN's current stock price of $7.95 by ALPN's total outstanding shares of 45,914,433.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.